This inventor holds 2 USPTO granted patents. Top assignees: The Catholic University of Korea, The Catholic University of Korea Industry-Academic Cooperation Foundation, Wonkwang University Center for Industry-Academy Cooperation. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: Kyoung In Jung: Innovator in Glaucoma Prediction Technology
Introduction
Kyoung In Jung is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of ophthalmology through his innovative work on glaucoma prediction systems. His research focuses on developing methods to predict the progression of glaucoma, a serious eye condition that can lead to vision loss.
Latest Patents
Kyoung In Jung holds a patent for a "Glaucoma progression prediction system and method." This system is designed to predict the progression of glaucoma by utilizing an examination module that captures images of the deep vessels of the eye. The system includes a measurement module that assesses deep vessel density in these images, an analysis module that tracks changes in vessel density over time, and a determination module that evaluates the progression of glaucoma based on these changes. He has 1 patent to his name.
Career Highlights
Kyoung In Jung is affiliated with the Catholic University of Korea Industry-Academic Cooperation Foundation. His work at this institution emphasizes the importance of collaboration between academia and industry to foster innovation in medical technology.
Collaborations
He has worked alongside notable colleagues such as Kyung Euy Hong and Chan Kee Park. Their combined expertise contributes to the advancement of research in glaucoma and other ophthalmic conditions.
Conclusion
Kyoung In Jung's contributions to glaucoma prediction technology highlight the importance of innovation in healthcare. His work not only aids in the early detection of glaucoma but also enhances the understanding of its progression, ultimately benefiting patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile